Researchers identify structure of agent that causes Alzheimer's and Parkinson's diseases

Alzheimer's disease - also called dementia - where memory and cognitive functions gradually decline due to deformation and death of neurons, and Parkinson's disease that causes tremors in hands and arms impeding normal movement are major neurodegenerative diseases. Recently, a research team at POSTECH has identified the structure of the agent that causes Alzheimer's and Parkinson's diseases to occur together.

A research team led by Professor Joon Won Park and Ph.D. candidate Eun Ji Shin of the Department of Chemistry at POSTECH investigated the surface structure of hetero-oligomers found in the overlap of Alzheimer's disease and Parkinson's disease, using an atomic force microscopy (AFM) to reveal their structural identity. This study was featured as the front cover paper in the latest issue of Nano Letters.

It is known that the pathological overlap of Alzheimer's disease and Parkinson's disease is associated with the formation of hetero-oligomers derived from amyloid-beta and alpha-synuclein. However, it was difficult to study the treatment due to technical limitations in observing their structure.

To this, the researchers used the AFM to observe the surface characteristic of the hetero-oligomer nano-aggregates derived from amyloid-beta, known as the biomarker of Alzheimer's disease, and alpha-synuclein, known as the biomarker of Parkinson's disease, at the single-molecule level.

When the research team investigated with four AFM tips immobilized with antibodies that recognize N-terminus or C-terminus of each peptide, it was confirmed that all aggregates were hetero-oligomers. In addition, in the case of hetero-oligomer, it was confirmed that the probability of recognizing the end of the peptide is higher than that of the homo-oligomer.

This result indicates that the end of each peptide has a bigger tendency to be located on the surface of hetero-oligomers than homo-oligomers, or that the ends of the peptides located on the surface have more degrees of freedom. That is, it can be confirmed that the aggregation between peptides is more loosely packed in the hetero-oligomer than in the homo-oligomer.

This study is the first study to observe the structure of protein disordered nano-aggregates, which has never been identified before, using the quadruple mapping with four AFM tips. It serves as experimental grounds to verify the hypothesis of hetero-oligomer aggregation. It can also be used in studies related to the overlapping phenomena of various neurodegenerative diseases other than Alzheimer's and Parkinson's.

Until now, there was no adequate method to analyze the nano-aggregates, making it impossible to elucidate the structural identity of heterogeneous aggregates. As the analysis method developed in this study is applicable to other amyloid protein aggregates, it will help to identify the cause of diseases such as Alzheimer's or the mad cow disease."

Joon Won Park, Professor, Pohang University of Science & Technology

Source:
Journal reference:

Shin, E J & Park, J W (2021) Nanoaggregates Derived from Amyloid-beta and Alpha-synuclein Characterized by Sequential Quadruple Force Mapping. Nano Letters. doi.org/10.1021/acs.nanolett.1c00058.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough discovery could lead to effective vaccine for S. aureus